Literature DB >> 24081787

Plurihormonal pituitary adenoma with concomitant adrenocorticotropic hormone (ACTH) and growth hormone (GH) secretion: a report of two cases and review of the literature.

Fahid Tariq Rasul1, Zane Jaunmuktane, Akbar Ali Khan, Rahul Phadke, Michael Powell.   

Abstract

Plurihormonal pituitary adenomas are tumours that show immunoreactivity for more than one hormone that cannot be explained by normal adenohypophysial cytodifferentiation. The most common combinations in these adenomas include growth hormone (GH), prolactin (PRL) and one or more glycoprotein hormone sub-units (β-TSH, β-FSH, β-LH and αSU). The authors report two cases of a plurihormonal pituitary adenoma expressing the rare combination of ACTH and GH. They both underwent successful transphenoidal hypophysectomy (TSH). Long-term post-operative follow-up revealed no evidence of tumour recurrence. Due to the multiple secretions and plurihormonal characteristics clinical diagnosis of composite pituitary adenomas can be difficult. The authors discuss the diagnosis and management of composite pituitary adenomas and review the literature regarding this rare phenomenon.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24081787     DOI: 10.1007/s00701-013-1890-y

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  3 in total

1.  Dopamine agonist-responsive Cushing's disease.

Authors:  Gurpreet Anand; Andrea Bink; Felix Beuschlein; Christoph Schmid
Journal:  BMJ Case Rep       Date:  2019-02-13

2.  Silent Corticotroph and Somatotroph Double Pituitary Adenoma: A Case Report and Review of Literature.

Authors:  Isabella L Pecorari; Lakshmi Priyanka Mahali; Abigail Funari; Roger Fecher; Nisha Suda; Vijay Agarwal
Journal:  J Neurol Surg Rep       Date:  2022-05-27

3.  A Preoperative MRI-Based Radiomics-Clinicopathological Classifier to Predict the Recurrence of Pituitary Macroadenoma Within 5 Years.

Authors:  Yu Zhang; Yuqi Luo; Xin Kong; Tao Wan; Yunling Long; Jun Ma
Journal:  Front Neurol       Date:  2022-01-05       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.